Stay updated on PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial
Sign up to get notified when there's something new on the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page.

Latest updates to the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new phase II study focusing on the combination of PEGPH20 and pembrolizumab for advanced pancreatic cancer patients with HA-high expression. Key collaborators and the principal investigator have been specified, and the revision number has been updated.SummaryDifference49%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
Stay in the know with updates to PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page.